Press Release
FOR IMMEDIATE RELEASE: January 2, 2008HyperBranch Receives CE Mark for OcuSeal™
Durham, NC (January 2, 2008) - HyperBranch Medical Technology, Inc. announced today that it has received a CE Mark for its OcuSeal™ product. OcuSeal liquid ocular bandage provides a protective barrier while stabilizing ocular wounds following surgical or non-surgical trauma and other ocular conditions. OcuSeal™ is intended for direct application on corneal, conjunctiva, and sclera surfaces to provide a temporary protective barrier in post-surgical, post-traumatic, and non-traumatic ocular conditions. The unique, single use device is terminally sterilized and allows for a simple one handed brush application. The CE mark for OcuSeal™ provides regulatory approval for the company to begin sales in Europe and potentially all other countries outside the US.
"Having the opportunity to begin sales is a major milestone for any small, developing company," said Conn. "It validates years of research and provides a revolutionary product not previously available to healthcare providers."
The HyperBranch OcuSeal™ product is synthetic hydrogel which polymerizes in a moist field, flows optimally depending on the application, and is bio-degradable as the tissue re-establishes itself. The biocompatible composition is stored at room temperature and is delivered through the custom applicator to meet the specific needs of the procedure. The intended users of OcuSeal™ are ophthalmologists in a surgical or clinical environment.
The Durham, North Carolina medical device company has also, been developing advanced surgical sealants for dura (brain), pleural (lung) and hernia mesh fixation. These products are all at various stages of clinical and pre-clinical development.
About HyperBranch Medical Technology, Inc.
HyperBranch Medical Technology, a privately-held company based in Durham, N.C., is developing innovative medical devices for the ophthalmology, general, and specialty surgery markets. The company is focused on the development of unique products based on its novel hydrogel technology. In addition to the ocular bandage, development work on HyperBranch's surgical sealant platform has led to the recognition of several novel hydrogel properties that suggest significant utility in a variety of additional clinical applications. For more information visit www.hyperbranch.com.
Please contact: Laura Jones, Administration Manager (LauraJ@hyperbranch.com) 919.433.3337